Scarica l'app Stockscreener
29.52
4.88%
1.375
Dopo l'orario di chiusura:
29.69
0.165
+0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.15
Aprire:
$28.33
Volume 24 ore:
2.78M
Relative Volume:
1.28
Capitalizzazione di mercato:
$5.12B
Reddito:
$23.16M
Utile/perdita netta:
$-354.30M
Rapporto P/E:
-11.70
EPS:
-2.5234
Flusso di cassa netto:
$-286.27M
1 W Prestazione:
-1.85%
1M Prestazione:
-9.82%
6M Prestazione:
-18.71%
1 anno Prestazione:
+78.18%
Intervallo 1D:
$28.33
$29.78
Intervallo di 1 settimana:
$27.73
$31.07
Portata 52W:
$13.78
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
29.52 | 5.12B | 23.16M | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2025-11-10 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-10-16 | Iniziato | Stifel | Hold |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Taking options instead of cash, a Cogent Biosciences (COGT) director receives a 759-option award. - Stock Titan
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network
A drug trial found responses in 65% of patients. The FDA will review it. - Stock Titan
Cogent Biosciences Announces FDA Acceptance of New Drug - GlobeNewswire
Cogent Biosciences Stock Price Forecast. Should You Buy COGT? - StockInvest.us
How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Cogent Biosciences (COGT) Edges Higher as Buyers Defend Key Support ZoneExtension Target - siam.in
Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia - marketscreener.com
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com India
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com Australia
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com Nigeria
$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today - Benzinga
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com South Africa
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com Canada
Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences (COGT) director sells 45K shares in 10b5-1 plan - stocktitan.net
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - Barchart.com
Cogent Biosciences (COGT) Slides 6.5% to $34.67 as Support and Resistance Levels Come into FocusETF Premium Discount - dars.gov.et
Cogent Biosciences Inc. (COGT) Peer Comparison – Compare with Others - Value Research
Cogent Biosciences (NASDAQ: COGT) director schedules option-led stock sale years ahead - Stock Titan
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat (NASDAQ:COGT) - Seeking Alpha
Cogent (COGT) Earnings Report: EPS Falls Short of Its Estimate in the Current Update; After Results: Shares Fall 0.91% in the Latest SessionAnalyst Earnings Estimate - vinanet.vn
Cogent (COGT) Earnings Reading: The Available Earnings Metric Delivers a Miss on the Day; Price Move - vinanet.vn
What Cogent Biosciences (COGT)'s Widening Net Losses Mean For Shareholders - simplywall.st
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences (COGT) Q2 Update Highlights Valuation Challenges Amid Strong Cash Reserves - GuruFocus
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses? - Sahm
COGT Maintained by Piper Sandler -- Price Target Raised to $55 - GuruFocus
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses? - simplywall.st
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - webull.com
Discipline and Rules-Based Execution in COGT Response - Stock Traders Daily
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences | ARS: Annual Report to Security Holders - Moomoo
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G - Stock Titan
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
COGT Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Guggenheim raises Cogent stock price target to $52 on FDA decisions - Investing.com
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences (COGT) Edges Higher to $38.98, Holding Ground Between Key Technical LevelsSmart Beta Flow - vinanet.vn
Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7%Should You Sell? - MarketBeat
Cogent Biosciences (COGT) Slides 6.81% to $38.70 as Biotech Risk-Off IntensifiesLate Stage Breakouts - vinanet.vn
Cogent Biosciences Q2 Loss Widens - Moomoo
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - Investing News Network
Cogent BiosciencesMay Offer Up To $400 Million In Common Stock Through Guggenheim Securities - TradingView
Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines - Stock Titan
Cogent Biosciences (NASDAQ:COGT) Shares Gap DownTime to Sell? - MarketBeat
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cogent Biosciences Inc Azioni (COGT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morris Arlene | Director |
Aug 27 '26 |
Sale |
37.12 |
45,510 |
1,689,493 |
0 |
| ARLENE MORRIS | Director |
Aug 27 '26 |
Proposed Sale |
36.72 |
45,510 |
1,671,127 |
0 |
| Fairmount Healthcare Fund II L | Director |
Mar 31 '26 |
Proposed Sale |
34.66 |
7,000,000 |
242,620,000 |
0 |
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Sale |
34.66 |
7,000,000 |
242,620,000 |
5,503,418 |
| Fairmount Funds Management LLC | Director |
Jan 22 '26 |
Sale |
36.40 |
3,500,000 |
127,400,000 |
5,503,418 |
| Fairmount Healthcare Fund II L | Director |
Jan 22 '26 |
Proposed Sale |
36.40 |
3,500,000 |
127,400,000 |
0 |
| Kearns Evan | Chief Legal Officer |
Dec 26 '25 |
Sale |
38.70 |
65,000 |
2,515,500 |
109,398 |
| Green John L. | Chief Financial Officer |
Dec 26 '25 |
Sale |
38.68 |
77,000 |
2,978,360 |
131,834 |
| Sachs Jessica | Chief Medical Officer |
Dec 26 '25 |
Sale |
38.70 |
82,642 |
3,198,245 |
133,938 |
| Robinson John Edward | Chief Scientific Officer |
Dec 26 '25 |
Sale |
38.74 |
90,000 |
3,486,600 |
140,002 |
2.18%
0.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):